CTMX — CytomX Therapeutics Share News
0.000.00%
Last trade - 00:00- $531.67m
- $201.39m
- $76.20m
Brief: CytomX Therapeutics FY Revenue USD 76.201 Million Vs. IBES Estimate USD 83.5 Million
U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft
Brief: Cytomx Therapeutics Announces Business Update And Company Milestones For 2026
Cancer immunotherapy firm CytomX's Q3 revenue falls
Brief: CytomX Therapeutics Q3 Revenue USD 5.963 Million Vs. IBES Estimate USD 11.6 Million
Brief: Cytomx Therapeutics Appoints Rachael Lester As Chief Business Officer
CytomX Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: CytomX Therapeutics Q2 Revenue USD 18.658 Million Vs. IBES Estimate USD 14.8 Million
CytomX Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
CytomX Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Cytomx Therapeutics Q1 Net Income USD 23.525 Million
Brief: Cytomx Announces Positive Interim Data From Phase 1 Dose Escalation Study Of Epcam Antibody Drug Conjugate (Cx-2051) Candidate In Patients With Advanced Colorectal Cancer (Crc)
CytomX Therapeutics Inc expected to post earnings of 12 cents a share - Earnings Preview
CytomX Therapeutics Inc expected to post earnings of 12 cents a share - Earnings Preview
Brief: Cytomx Therapeutics Presents Preclinical Data For mRNA Encoded Masked Il-12 Molecule In Collaboration With Moderna
CytomX Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
CytomX Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
CytomX Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary